Alpha-synuclein (α-Syn) overexpression and misfolding/aggregation in degenerating dopaminergic neurons have long been implicated in Parkinson’s disease (PD). The neurotoxicity of α-Syn is enhanced by iron (Fe) and other pro-oxidant metals, leading to generation of reactive oxygen species in PD brain. Although α-Syn is predominantly localized in presynaptic nerve terminals, a small fraction exists in neuronal nuclei. However, the functional and/or pathological role of nuclear α-Syn is unclear. Following up on our earlier report that α-Syn directly binds DNA in vitro, here we confirm the nuclear localization and chromatin association of α-Syn in neurons using proximity ligation and chromatin immunoprecipitation analysis. Moderate (∼2-fold) increase in α-Syn expression in neural lineage progenitor cells (NPC) derived from induced pluripotent human stem cells (iPSCs) or differentiated SHSY-5Y cells caused DNA strand breaks in the nuclear genome, which was further enhanced synergistically by Fe salts. Furthermore, α-Syn required nuclear localization for inducing genome damage as revealed by the effect of nucleus versus cytosol-specific mutants. Enhanced DNA damage by oxidized and misfolded/oligomeric α-Syn suggests that DNA nicking activity is mediated by the chemical nuclease activity of an oxidized peptide segment in the misfolded α-Syn. Consistent with this finding, a marked increase in Fe-dependent DNA breaks was observed in NPCs from a PD patient-derived iPSC line harboring triplication of the SNCA gene. Finally, α-Syn combined with Fe significantly promoted neuronal cell death. Together, these findings provide a novel molecular insight into the direct role of α-Syn in inducing neuronal genome damage, which could possibly contribute to neurodegeneration in PD.
TheilletFX, BinolfiA, BekeiB, MartoranaA, RoseHM, StuiverM, VerziniS, LorenzD, van RossumM, GoldfarbD, SelenkoP (2016) Structural disorder of monomeric α-synuclein persists in mammalian cells. Nature530, 45–50.
2.
RaghavanR, de KruijffL, SterrenburgMD, RogersBB, HladikCL, WhiteCL3rd (2004) Alpha-synuclein expression in the developing human brain. Pediatr Dev Pathol7, 506–516.
OczkowskaA, KozubskiW, LianeriM, DorszewskaJ (2013) Mutations in PRKN and SNCA genes important for the progress of Parkinson’s disease. Curr Genomics14, 502–517.
6.
HirschEC, BrandelJP, GalleP, Javoy-AgidF, AgidY (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: An X-ray microanalysis. J Neurochem56, 446–451.
7.
DaviesKM, BohicS, CarmonaA, OrtegaR, CottamV, HareDJ, FinbergJP, ReyesS, HallidayGM, MercerJF, DoubleKL (2014) Copper pathology in vulnerable brain regions in Parkinson’s disease. Neurobiol Aging35, 858–866.
8.
SoficE, LangeKW, JellingerK, RiedererP (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett142, 128–130.
9.
PengY, WangC, XuHH, LiuYN, ZhouF (2010) Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem104, 365–370.
10.
RoseF, HodakM, BernholcJ (2011) Mechanism of copper(II)-induced misfolding of Parkinson’s disease protein. Sci Rep1, 11.
11.
SneadD, EliezerD (2014) Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol23, 292–313.
12.
ColeNB, MurphyDD, LebowitzJ, Di NotoL, LevineRL, NussbaumRL (2005) Metal-catalyzed oxidation of alpha-synuclein: Heling to define the relationship between oligomers, protofibrils, and filaments. J Biol Chem280, 9678–9690.
13.
GaoHM, KotzbauerPT, UryuK, LeightS, TrojanowskiJQ, LeeVM (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci28, 7687–7698.
14.
MiottoMC, RodriguezEE, Valiente-GabioudAA, Torres-MonserratV, BinolfiA, QuintanarL, ZweckstetterM, GriesingerC, FernandezCO (2014) Site-specific copper-catalyzed oxidation of α-synucle, Tightening the link between metal binding androtein oxidative damage in Parkinson’s disease. Inorg Chem53, 4350–4358.
15.
BinolfiA, LimatolaA, VerziniS, KostenJ, TheilletFX, RoseHM, BekeiB, StuiverM, van RossumM, SelenkoP (2016) Intracellular repair of oxidation-damaged α-synuclein fails to target C-terminal modification sites. Nat Commun7, 10251.
16.
MaroteauxL, CampanelliJT, SchellerRH (1988) Synuclein: A neuron-secific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci8, 2804–2815
17.
TanjiK, MoriF, ImaizumiT, YoshidaH, MatsumiyaT, TamoW, YoshimotoM, OdagiriH, SasakiM, TakahashiH, SatohK, WakabayashiK (2002) Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathol Int52, 572–577.
18.
GoersJ, Manning-BogAB, McCormackAL, MillettIS, DoniachS, Di MonteDA, UverskyVN, FinkAL (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry42, 8465–8471.
19.
ZhangL, ZhangC, ZhuY, CaiQ, ChanP, UédaK, YuS, YangH (2008) Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: An immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Res1244, 40–52.
20.
LinBY, KaoMC (2015) Therapeutic applications of the TAT-mediated protein transduction system for complex I deficiency and other mitochondrial diseases. Ann N Y Acad Sci1350, 17–28.
21.
SiddiquiA, ChintaSJ, MallajosyulaJK, RajagopolanS, HansonI, RaneA, AndersenJK (2012) Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: Implications for Parkinson’s disease. Free Radic Biol Med53, 993–1003.
22.
MaKL, SongLK, YuanYH, ZhangY, HanN, GaoK, ChenNH (2014) The nuclear accumulation of alpha-synuclein is mediated by importin alpha and promotes neurotoxicity by accelerating the cell cycle. Neuropharmacology82, 132–142.
23.
KontopoulosE, ParvinJD, FeanyMB (2006) Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet15, 3012–3023.
24.
XuS, ZhouM, YuS, CaiY, ZhangA, UédaK, ChanP (2006) Oxidative stress induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. Biochem Biophys Res Commun342, 330–335.
25.
RousseauxMW, de HaroM, Lasagna-ReevesCA, De MaioA, ParkJ, Jafar-NejadP, Al-RamahiI, SharmaA, SeeL, LuN, Vilanova-VelezL, KlischTJ, WestbrookTF, TroncosoJC, BotasJ, ZoghbiHY (2016) TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau. eLife5, doi: 10.7554/eLife.19809
26.
HegdeML, Jagannatha RaoKS (2003) Challenges and complexities of alpha-synuclein toxicity: Mew postulates in unfolding the mystery associated with Parkinson’s disease. Arch Biochem Biophys418, 169–178.
27.
HegdeML, RaoKS (2007) DNA induces folding in alpha-synuclein: Understanding the mechanism using chaerone property of osmolytes. Arch Biochem Biophys464, 57–69.
28.
VasudevarajuP, GuerreroE, HegdeML, CollenTB, BrittonGB, RaoKS (2012) New evidence on α-synuclein and Tau binding to conformation and sequence specific GC* rich DNA: Relevance to neurological disorders. J Pharm Bioallied Sci4, 112–117.
29.
HegdeML, GuptaVB, AnithaM, HarikrishnaT, ShankarSK, MuthaneU, Subba RaoK, Jagannatha RaoKS (2006) Studies on genomic DNA topology and stability in brain regions of Parkinson’s disease. Arch Biochem Biophys449, 143–156.
30.
YasuharaT, HaraK, SethiKD, MorganJC, BorlonganCV (2007) Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats. Brain Res1133, 49–52.
31.
WangD, YuT, LiuY, YanJ, GuoY, JingY, YangX, SongY, TianY (2016) DNA damage preceding dopamine neuron degeneration in A53T human α-synuclein transgenic mice. Biochem Biophys Res Commun481, 104–110.
32.
WangT, WeiJJ, SabatiniDM, LanderES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science343, 80–84.
33.
RhinnH, QiangL, YamashitaT, RheeD, ZolinA, VantiW, AbeliovichA (2012) Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson’s disease pathology. Nat Commun3, 1084.
34.
DettmerU, NewmanAJ, LuthES, BartelsT, SelkoeD (2013) In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells. J Biol Chem288, 6371–6385.
SenguptaS, ManthaAK, MitraS, BhakatKK (2011) Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene30, 482–493.
37.
HegdePM, DuttaA, SenguptaS, MitraJ, AdhikariS, TomkinsonAE, LiGM, BoldoghI, HazraTK, MitraS, HegdeML (2015) The C-terminal domain (CTD) of human DNA glycosylase NEIL1 is required for forming BERosome repair complex with DNA replication proteins at the replicating genome: DOMINANT NEGATIVE FUNCTION OF THE CTD. J Biol Chem290, 20919–20933.
38.
HegdeML, HegdePM, BellotLJ, MandalSM, HazraTK, LiGM, BoldoghI, TomkinsonAE, MitraS (2013) Prereplicative repair of oxidized bases in the human genome is mediated by NEIL1 DNA glycosylase together with replication proteins. Proc Natl Acad Sci U S A110, E3090–E3099.
39.
KovalenkoOA, SantosJH (2009) Analysis of oxidative damage by gene-specific quantitative PCR.Unit 19. Curr Protoc Hum GenetChapter 19, Unit 19.1.
40.
SarkerAH, ChatterjeeA, WilliamsM, LinS, HavelC, JacobP3rd, BoldoghI, HazraTK, TalbotP, HangB (2014) NEIL2 protects against oxidative DNA damage induced by sidestream smoke in human cells. PLoS One9, e90261.
41.
MosbaughDW, LinnS (1982) Characterization of the action of Escherichia coli DNA polymerase I at incisions produced by repair endodeoxyribonucleases. J Biol Chem257, 575–583.
42.
DengG, WuR (1983) Terminal transferase: Use of the tailing of DNA and for in vitro mutagenesis. Methods Enzymol100, 96–116.
43.
MandavilliBS, RaoKS (1996) Accumulation of DNA damage in aging neurons occurs through a mechanism other than apoptosis. J Neurochem67, 1559–1565.
44.
PandeyA, VishnoiK, MahataS, TripathiSC, MisraSP, MisraV, MehrotraR, DwivediM, BhartiAC (2015) Berberine and curcumin target survivin and STAT3 in gastric cancer cells and synergize actions of standard chemotherapeutic 5-fluorouracil. Nutr Cancer67, 1293–1304.
45.
FredrikssonS, GullbergM, JarviusJ, OlssonC, PietrasK, GustafsdóttirSM, OstmanA, LandegrenU (2002) Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol20, 473–477.
46.
OrtegaR, CarmonaA, RoudeauS, PerrinL, DučićT, CarboniE, BohicS, CloetensP, LingorP (2016) α-synuclein over-expression induces increased iron accumulation and redistribution in iron-exposed neurons. Mol Neurobiol53, 1925–1934.
47.
WinnerB, JappelliR, MajiSK, DesplatsPA, BoyerL, AignerS, HetzerC, LoherT, VilarM, CampioniS, TzitzilonisC, SoragniA, JessbergerS, MiraH, ConsiglioA, PhamE, MasliahE, GageFH, RiekR (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA108, 4194–4199.
48.
PrestwichEG, RoyMD, RegoJ, KelleySO (2005) Oxidative DNA strand scission induced by peptides. Chem Biol12, 695–701.
49.
QianY, ZhengY, AbrahamL, RamosKS, Tiffany-CastiglioniE (2005) Differential profiles of copper-induced ROS generation in human neuroblastoma and astrocytoma cells. Brain Res Mol Brain Res134, 323–332.
50.
ChouCH, FanHC, HuengDY (2015) Potential of neural stem cell-based therapy for Parkinson’s disease. Parkinsons Dis2015, 571475.
51.
FlierlA, OliveiraLM, Falomir-LockhartLJ, MakSK, HesleyJ, SoldnerF, Arndt-JovinDJ, JaenischR, LangstonJW, JovinTM, SchüleB (2014) Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication. PLoS One9, e112413.
52.
DixonSJ, LembergKM, LamprechtMR, SkoutaR, ZaitsevEM, GleasonCE, PatelDN, BauerAJ, CantleyAM, YangWS, MorrisonB3rd, StockwellBR (2012) Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell149, 1060–1072.
53.
GuineySJ, AdlardPA, BushAI, FinkelsteinDI, AytonS (2017) Ferroptosis and cell death mechanisms in Parkinson’s disease. Neurochem Int104, 34–48.
54.
TuszynskaI, MagnusM, JonakK, DawsonW, BujnickiJM (2015) NPDock: A web server for protein-nucleic acid docking. Nucleic Acids Res43, W425–W430.
55.
UlmerTS, BaxA, ColeNB, NussbaumRL (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem280, 9595–9603.
56.
BrennanRG, MatthewsBW (1989) The helix-turn-helix DNA binding motif. J Biol Chem264, 1903–1906.
57.
MoriyamaT, SangelP, YamaguchiH, ObuseC, MiyamotoY, OkaM, YonedaY (2015) Identification and characterization of a nuclear localization signal of TRIM28 that overlaps with the HP1 box. Biochem Biophys Res Commun462, 201–207.
58.
BunchH, CalderwoodSK (2015) TRIM28 as a novel transcriptional elongation factor. BMC Mol Biol16, 14.
59.
SangchotP, SharmaS, ChetsawangB, PorterJ, GovitrapongP, EbadiM (2002) Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci24, 143–153.
60.
Bharathi, IndiSS, RaoKS (2007) Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study. Neurosci Lett424, 78–82.
61.
Bharathi, RaoKS (2007) Thermodynamics imprinting reveals differential binding of metals to alpha-synuclein: Relevance toarkinson’s disease. Biochem Biophys Res Commun359, 115–120.
62.
HegdeML, AnithaS, LathaKS, MustakMS, SteinR, RavidR, RaoKS (2004) First evidence for helical transitions in supercoiled DNA by amyloid Beta Peptide (1-42) and aluminum: A new insight in understanding Alzheimer’s disease. J Mol Neurosci22, 19–31.
63.
GuptaVB, MonicaFS, BerrocalR, RaoKS, RaoKS (2013) Studies on the mechanism of the DNA nicking property of amyloid-β40: Implications in Alzheimer’s disease. J Alzheimers Dis33, 1059–1071.
64.
YinS, FanX, YuS, LiC, SyMS (2008) Binding of recombinant but not endogenous prion protein to DNA causes DNA internalization and expression in mammalian cells. J Biol Chem283, 25446–25454.
